Home   Login

Lacoste Jumpers

"Taken together, these data showing AR9281's safety and attractive pharmaceutic properties in normal healthy volunteers and strong evidence of its efficacy in animal models of type 2 diabetes support the further development of this novel drug candidate for the treatment of type 2 diabetes," said James A. Lacoste Jumpers Sabry, MD, PhD, Arete's President and Chief Executive Officer. "We anticipate that the results from our ongoing phase IIa clinical program in pre diabetic patients will establish proof of concept that sEH inhibition modulates glucose metabolism or blood pressure in patients with impaired glucose tolerance and hypertension to further corroborate the clinical importance of this novel therapeutic approach."

AR9281, an orally administered soluble epoxide hydrolase Lacoste Shirts For Ladies

Lacoste Jumpers

In addition, clinical data demonstrate a linear relationship between AR9281 exposure and blood sEH activity.

Three Posters Presented at ADA

Lacoste Jumpers

Lacoste Jumpers

Lacoste Jumpers

2 Diabetes Phase II Study in Patients with Impaired Glucose Tolerance Designed to Confirm Therapeutic Activity Progenics Pharmaceuticals, Inc. as Senior Vice President of Drug Discovery Celator Pharmaceuticals, Inc. Presents Data on the Activity of CPX 351 Against Leukemia at the European Hematology Association Congress.

Lacoste Jumpers

Lacoste Jumpers

The data presented by Arete scientists and colleagues are described as follows.

´╗┐Arete Therapeutics Presents Positive Clinical and Preclinical Data for AR9281

The Phase I clinical program for AR9281, consisting of two double blind, placebo controlled studies, demonstrated that AR9281 was safe and well tolerated in healthy volunteers. The studies met all safety, tolerability, pharmacokinetic and pharmacodynamic endpoints. In addition, AR9281 has shown favorable results in various published and proprietary in vitro and in vivo assays for potency, selectivity, efficacy, ADME, toxicity and safety.

Presented at the 69th Scientific Sessions of the American Diabetes Association (ADA) the data demonstrate that AR9281 exerts sEH mechanism based improvement in glucose tolerance in preclinical models of type 2 diabetes. Polo T Shirts Combo Online India

Lacoste Jumpers

Lacoste Jumpers

Arete Therapeutics is a privately held biotechnology company dedicated to the discovery and development of novel drugs to treat type 2 diabetes, hypertension and inflammatory disorders. It is the world's leading company focused on sEH, an important enzyme for the metabolism of arachidonic acid that plays an essential role in metabolic, inflammatory and cardiovascular physiology. The Company has raised a total of over $51 million in Series A financing led by Frazier Healthcare Ventures, Alta Partners, Three Arch Partners, Burrill Company and Altitude Life Science Ventures.

(sEH) inhibitor, operates within the third branch of the arachidonic acid pathway and represents a novel and potentially more effective approach to treating type 2 diabetes, hypertension and inflammatory disease. The first two branches of this critical regulatory pathway have been targeted by several commercially successful marketed anti inflammatory drugs including Aspirin(R) (acetylsalicylic acid), Motrin(R) (ibuprofen), Singulair(R) (montelukast) and Celebrex(R) (celecoxib). AR9281 has demonstrated an excellent safety profile and activity in multiple animal models of type 2 diabetes, and has the advantage of inhibiting a novel drug target that differentiates it from currently marketed diabetes medications. With this promising drug profile, AR9281 has the potential to provide safe and effective therapy for patients with type 2 diabetes either as monotherapy or in combination with existing treatment regimens.

SOUTH SAN FRANCISCO, Calif., June 9 /PRNewswire/ Arete Therapeutics Inc. today announced the presentation of three posters that validate the mechanistic activity and therapeutic potential of the company's lead drug candidate, AR9281, an orally administered soluble epoxide hydrolase (sEH) inhibitor that is in a Phase II clinical program for the treatment of type 2 diabetes. sEH is an enzyme involved in the metabolism of arachidonic acid, a key signaling molecule implicated in diabetes, hypertension and inflammatory disorders.

Results Reported at the American Diabetes Association Meeting Validate Mechanistic and Therapeutic Potential of sEH Inhibitor in Treating Type 2 Diabetes

Arete Therapeutics Initiates Phase IIa Clinical Trial for AR9281, a Novel s EH Inhibitor to Treat Type Womens Polo Tops Uk

AR9281 Phase II Program Underway

Arete is conducting a Phase IIa multicenter, double blind, placebo controlled study of AR9281 in pre diabetic patients with impaired glucose tolerance, mild obesity and mild to moderate hypertension. All 150 enrolled patients will be treatment naive for type 2 diabetes medications. The trial is evaluating two schedules of AR9281 and placebo using a parallel design to determine the feasibility of twice a day dosing. Each patient receives 28 days of treatment. Endpoints for the trial include safety, tolerability, reduction of blood pressure and various measures of glucose and lipid metabolism, with results expected in the first quarter of 2010.

Lacoste Jumpers

Lacoste Jumpers

Lacoste Jumpers

Polo Shirts Fred Perry

Adidas Long Sleeve Striped Top
Adidas Hoodie Grey And Black
Adidas Hoodies Black And White
Lacoste Clothes Offer

Polo Shirts For Boys

Adidas Red Hoodie Womens
Womens Lacoste Shirts

Printed Work Polo Shirts Uk

Adidas Pink T Shirt Dress
Fred Perry T Shirt Black

Fred Perry Navy Jacket

Lacoste Red For Men

Lacoste Glasses Black

Lacoste Glasses 2018

Home / Lacoste Jumpers

Copyright 2011 Neonatal, Paediatric and Child Health Nursing   Terms Of Use  Privacy Statement